News

BioInvent and ThromboGenics have initiated the enrollment of second cohort of patients for their phase-II trial of TB-402. TB-402 is a novel, long acting anticoagulant for the prevention

Bayer Schering and Bayer HealthCare together with Schering have filed a patent infringement lawsuit in the US Federal Court in the District of Delaware against Teva Pharmaceuticals and

Sanofi-aventis has received FDA approval for Multaq (dronedarone) 400mg tablets for patients with atrial fibrillation (AF) or atrial flutter (AFL). The FDA approval is based on five international,

Interleukin has executed an agreement to sell the Alan James Group assets of its subsidiary to Pep Products, a subsidiary of Nutraceutical, for approximately $4.6 million. Lewis Bender,

Prasco has entered into a distribution and supply agreement with Axcan for authorized generic versions of URSO 250 and URSO Forte Scored family of products. Prasco plans to

Alcon has discontinued development of anecortave acetate meant for the reduction of intraocular pressure (IOP) associated with glaucoma. The company recently reviewed interim efficacy and safety data from

MorphoSys and the University of Melbourne have entered into an agreement to cooperate on investigating new therapeutic applications for MorphoSys’s MOR103 program. MOR103, a HuCAL antibody against human

Myriad Genetics has completed the spin off of Myriad Pharmaceuticals. Also, the company has received a Private Letter Ruling from the Internal Revenue Service. It states that the

Acura and King Pharmaceuticals have announced that FDA has issued a Complete Response Letter regarding the New Drug Application (NDA) for Acurox Tablets CII. Its an immediate release